<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article194</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PROWESS" style="display:block; margin-bottom:10px;">PROWESS Original</a></li>
<h2><strong>PROWESS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Drotrecogin Alfa (Activated) in Severe Sepsis".  <br/>
The New England Journal of Medicine. 2001. 344(10):699-709.<br/>
PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does treatment with drotrecogin alfa (activated) reduce mortality in patients with severe sepsis?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Treatment with drotrecogin alfa (activated) significantly reduces mortality in patients with severe sepsis but may be associated with an increased risk of bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Severe sepsis, a generalized inflammatory and procoagulant response to infection, results in a high rate of mortality despite advancements in critical care. Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. This phase 3 trial assessed its efficacy in reducing mortality rates in patients with severe sepsis.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
No guidelines are discussed in this article.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Randomized, double-blind, placebo-controlled, multicenter trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
Inclusion Criteria<br/>
- Known or suspected infection with clinical evidence<br/>
- Systemic inflammation and organ failure due to acute infection within 24 hours<br/>
- Treatment within 24 hours of meeting inclusion criteria<br/>
<br/>
Exclusion Criteria<br/>
Not described in detail in the provided text.<br/>
<br/>
Baseline Characteristics<br/>
- Demographics and severity of disease were similar between placebo and treatment groups.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients were randomly assigned to receive either placebo or drotrecogin alfa activated (24 μg/kg/hour) for 96 hours.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
Primary Outcome<br/>
- Mortality from any cause at 28 days after the initiation of the infusion.<br/>
<br/>
Secondary Outcomes<br/>
- Reduction in plasma D-dimer and serum interleukin-6 levels, indicating a reduced procoagulant state and decreased inflammation in the treatment group.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Potential for increased risk of bleeding.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Eli Lilly.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The article would have sections on Design, Population, additional Criticisms, and other further reading references not provided in the abstract.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
